晚期肺鳞癌免疫治疗：现状与未解问题

文章预览

SCI 24 December 2025 Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions (Nature Reviews Clinical Oncology, IF: 81.1) Yibei Wang, Mohammed Safi, Fred R. Hirsch, Shun Lu, Solange Peters, Ramaswamy Govindan, Rafael Rosell, Keunchil Park & Jianjun J. Zhang CORRESPONDENCE TO: kp4663@gmail.com; JZhang20@mdanderson.org Abstract 摘要 Immune-checkpoint inhibitors (ICIs) have transformed the treatment paradigm for advanced-stage squamous non-small-cell lung cancer (LUSC), a histological subtype associated with inferior outcomes compared with lung adenocarcinoma. However, only a subset of patients derive durable clinical benefit. In the first-line setting, multiple ICI regimens are available, including anti-PD-(L)1 antibodies as monotherapy, in combination with chemotherapy, or with an anti-CTLA4 antibody with or without chemotherapy. Several important questions persist regarding the optimal regimen for individual patients, particularly ………………………………